TITLE

An Open-Label Study of Aripiprazole for Methamphetamine Induced Psychosis

AUTHOR(S)
Sulaiman, Ahmad Hatim; Gill, Jesjeet Singh; Said, Mas Ayu; Habil, Mohamad Hussain; Zainal, Nor Zuraida; Ng Chong Guan
PUB. DATE
June 2012
SOURCE
Klinik Psikofarmakoloji Bulteni;Jun2012, Vol. 22 Issue 2, p121
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
An open-label study of aripiprazole for methamphetamine induced psychosis Objective: This study aimed to explore the therapeutic effects and tolerability of aripiprazole in the treatment of psychosis among methamphetamine dependent patients. Methods: This was an open label single arm prospective study conducted at the University Malaya Medical Centre (UMMC). The study subjects included treatment naive patients with a current diagnosis of methamphetamine dependence with co-occurring acute psychotic symptoms based on the Diagnostic and Statistical Manual of Mental Disorders-IV (DSMIV). Eligible patients were treated with an initial dose of 5-10 mg aripiprazole followed by flexible doses (5-15mg/day) from day 2 to 14. Results: Out of 49 patients enrolled, 41 patients (83.7%) completed the study. At baseline the mean PANSS total score was 79.2±13.7 and the mean CGI-S score was 4.3±0.5. There was a statistically significant decline in the mean PANSS-total and CGI-S scores over the course of the study. The mean reduction was 27.6±21.4 point (p<0.05, 95% CI (-34.8, -20.4)) from baseline on day 14 for total PANSS score and 2.0±1.2 point (p<0.05, 95% CI (-2.4, -1.6) for CGI-S. Aripiprazole was generally well tolerated during the study. Adverse events were reported in 10 (20.4%) patients. No statistically significant changes were noted with respect to movement-related adverse events. Conclusions: This study found that aripiprazole improved the psychotic symptoms associated with methamphetamine use. It was generally well tolerated with mild to moderate adverse events. Based on these results aripiprazole might be an effective and safe option for the treatment of methamphetamine induced psychosis.
ACCESSION #
78348655

 

Related Articles

  • Review of depot aripiprazole for schizophrenia. Bilal Motiwala, Farha; Stasia Siscoe, Kim; El-Mallakh, Rif S. // Patient Preference & Adherence;2013, Vol. 7, p1181 

    Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will...

  • Psychopathological dimensions in first-episode psychoses: From the trunk to the branches and leaves. Cuesta, Manuel J.; Peralta, Victor; Gil, Patxi; Artamendi, Maria // European Archives of Psychiatry & Clinical Neuroscience;2003, Vol. 253 Issue 2, p73 

    Background: Dimensional frameworks for structuring psychopathology have been formulated in recent years to overcome classification problems of categorical approaches. However, few studies have addressed the dilemma of hierarchy within symptoms or dimensions in psychosis. Methods: This study was...

  • In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia. Kaczor, Agnieszka A.; Kȩdzierska, Ewa; Koszła, Oliwia; Targowska-Duda, Katarzyna M. // Biomolecules (2218-273X);Jan2020, Vol. 10 Issue 1, p1 

    Schizophrenia (SZ) is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms, and is not satisfactorily treated by current antipsychotics. Progress in understanding the basic pathomechanism of the disease has been hampered by the lack of appropriate models. In...

  • Are Lay People Good at Recognising the Symptoms of Schizophrenia? Erritty, Philip; Wydell, Taeko N. // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Aim: The aim of this study was to explore the general public's perception of schizophrenia symptoms and the need to seek- help for symptoms. The recognition (or 'labelling') of schizophrenia symptoms, help-seeking behaviours and public awareness of schizophrenia have been suggested as...

  • Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Jorge L. Juncos; Vicki J. Roberts; Marian L. Evatt; Rita D. Jewart; Colleen D. Wood; Larry S. Potter; Hann-Chang Jou; Paul P. Yeung // Movement Disorders;Jan2004, Vol. 19 Issue 1, p29 

    Twenty-nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24-week, single-center, open-label trial to assess the efficacy of quetiapine (12.5–400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive...

  • Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study. Iasevoli, Felice; Buonaguro, Elisabetta F.; Marconi, Massimo; Di Giovambattista, Emanuela; Rapagnani, Maria Paola; De Berardis, Domenico; Martinotti, Giovanni; Mazza, Monica; Balletta, Raffaele; Serroni, Nicola; Di Giannantonio, Massimo; de Bartolomeis, Andrea; Valchera, Alessandro // ISRN Otolaryngology;2014, p1 

    Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or...

  • The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Nyth, Anna Lena; Gottfries, Carl Gerhard; Nyth, A L; Gottfries, C G // British Journal of Psychiatry;Dec90, Vol. 157, p894 

    In this multicenter study, the clinical efficacy of citalopram was investigated in 98 patients with moderate AD/SDAT or VD using a combined double-blind and open technique with placebo and citalopram. Analyses were made for each diagnosis after four weeks of double-blind treatment. Patients with...

  • Neurobiological Evidence Supporting Glutamate's Role in Pediatric Obsessive Compulsive Disorder. MacMaster, Frank P.; Rosenberg, David R. // Child & Adolescent Psychopharmacology News;2010, Vol. 15 Issue 6, p6 

    The article discusses research on the role of glutamate in the treatment of pediatric obsessive compulsive disorder (OCD). Based on a study, OCD begins during childhood and adolescence at the age ranges from 9 to 11 years in boys and from 11 to 13 years in girls. Several studies reveal that...

  • Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae. Okamoto, Hideki; Chino, Atsushi; Hirasaki, Yoshiro; Ueda, Keigo; Iyo, Masaomi; Namiki, Takao // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p151 

    Background: Yokukan-san, a Japanese traditional herbal (Kampo) prescription, has recently gathered increasing attention due to accumulating reports showing its remarkable efficacy in treating a wide variety of diseases refractory to conventional medicine as well as the behavioral and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics